JP2017502069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502069A5 JP2017502069A5 JP2016545898A JP2016545898A JP2017502069A5 JP 2017502069 A5 JP2017502069 A5 JP 2017502069A5 JP 2016545898 A JP2016545898 A JP 2016545898A JP 2016545898 A JP2016545898 A JP 2016545898A JP 2017502069 A5 JP2017502069 A5 JP 2017502069A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disorder
- disorders
- dementia
- salt form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical group 0.000 claims 19
- 206010012289 Dementia Diseases 0.000 claims 17
- 208000010877 cognitive disease Diseases 0.000 claims 15
- 208000028698 Cognitive impairment Diseases 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 208000035475 disorder Diseases 0.000 claims 13
- 208000020925 Bipolar disease Diseases 0.000 claims 9
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 6
- 208000019695 Migraine disease Diseases 0.000 claims 6
- 208000019022 Mood disease Diseases 0.000 claims 6
- 208000007101 Muscle Cramp Diseases 0.000 claims 6
- 208000005392 Spasm Diseases 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 6
- 230000027288 circadian rhythm Effects 0.000 claims 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 6
- 206010027599 migraine Diseases 0.000 claims 6
- 230000036407 pain Effects 0.000 claims 6
- 201000000980 schizophrenia Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 3
- 208000031091 Amnestic disease Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 201000006062 Asperger syndrome Diseases 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 3
- 208000020706 Autistic disease Diseases 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 3
- 206010048962 Brain oedema Diseases 0.000 claims 3
- 102100034356 Casein kinase I isoform alpha-like Human genes 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 3
- 206010019196 Head injury Diseases 0.000 claims 3
- 208000010496 Heart Arrest Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000004404 Intractable Pain Diseases 0.000 claims 3
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 3
- 206010026749 Mania Diseases 0.000 claims 3
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000028389 Nerve injury Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 241000208125 Nicotiana Species 0.000 claims 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 3
- 206010065016 Post-traumatic pain Diseases 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010038923 Retinopathy Diseases 0.000 claims 3
- 206010041250 Social phobia Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 3
- 208000009205 Tinnitus Diseases 0.000 claims 3
- 206010044565 Tremor Diseases 0.000 claims 3
- 206010046543 Urinary incontinence Diseases 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 230000006986 amnesia Effects 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 210000004227 basal ganglia Anatomy 0.000 claims 3
- 229940049706 benzodiazepine Drugs 0.000 claims 3
- 230000006931 brain damage Effects 0.000 claims 3
- 231100000874 brain damage Toxicity 0.000 claims 3
- 208000006752 brain edema Diseases 0.000 claims 3
- 208000029028 brain injury Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 210000000349 chromosome Anatomy 0.000 claims 3
- 229960003920 cocaine Drugs 0.000 claims 3
- 230000001054 cortical effect Effects 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 231100000040 eye damage Toxicity 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 208000029364 generalized anxiety disease Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 208000016354 hearing loss disease Diseases 0.000 claims 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims 3
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 201000003631 narcolepsy Diseases 0.000 claims 3
- 230000008764 nerve damage Effects 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 229960002715 nicotine Drugs 0.000 claims 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 208000019906 panic disease Diseases 0.000 claims 3
- 208000033300 perinatal asphyxia Diseases 0.000 claims 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 230000001568 sexual effect Effects 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 208000020431 spinal cord injury Diseases 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 231100000886 tinnitus Toxicity 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 3
- 230000008673 vomiting Effects 0.000 claims 3
- 101150047910 CSNK1D gene Proteins 0.000 claims 2
- 206010039897 Sedation Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 229940035676 analgesics Drugs 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 230000036280 sedation Effects 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 201000007034 advanced sleep phase syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical group [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 1
- 229940055742 indium-111 Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940056501 technetium 99m Drugs 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 0 *c(cc1)ccc1-c1n[n](ccc(N(*)*)n2)c2c1-c1ccncc1 Chemical compound *c(cc1)ccc1-c1n[n](ccc(N(*)*)n2)c2c1-c1ccncc1 0.000 description 9
- NDYIDNFYFMCFSD-UHFFFAOYSA-N CN(CC1)CCN1c(cc[n]1nc2-c(cc3)ccc3F)nc1c2-c1ccncc1 Chemical compound CN(CC1)CCN1c(cc[n]1nc2-c(cc3)ccc3F)nc1c2-c1ccncc1 NDYIDNFYFMCFSD-UHFFFAOYSA-N 0.000 description 2
- FAFUZOISHFDUSN-UHFFFAOYSA-N C#Cc1c2[s]c(NC(Cc3ccccc3)=O)nc2ccc1 Chemical compound C#Cc1c2[s]c(NC(Cc3ccccc3)=O)nc2ccc1 FAFUZOISHFDUSN-UHFFFAOYSA-N 0.000 description 1
- NCGPQHYINHQFQO-UHFFFAOYSA-N CC(C)(C)c1ccc2nc(NC(Cc(cc3)ccc3NC(C)=O)=O)[s]c2c1 Chemical compound CC(C)(C)c1ccc2nc(NC(Cc(cc3)ccc3NC(C)=O)=O)[s]c2c1 NCGPQHYINHQFQO-UHFFFAOYSA-N 0.000 description 1
- VJOVPVHNPNSSFB-UHFFFAOYSA-N CC(Nc1ccc(CC(/N=C(/N)\Nc2nc3ccccc3[nH]2)=O)cc1)=O Chemical compound CC(Nc1ccc(CC(/N=C(/N)\Nc2nc3ccccc3[nH]2)=O)cc1)=O VJOVPVHNPNSSFB-UHFFFAOYSA-N 0.000 description 1
- ZWLSFGVKQKSTIV-UHFFFAOYSA-N CC(c1ccc2nc(NC(Cc(cc3)ccc3NC(CCCc3ccc4nc(NC(Cc(cc5)ccc5NC(C)=O)=O)[s]c4c3)=O)=O)[s]c2c1)=O Chemical compound CC(c1ccc2nc(NC(Cc(cc3)ccc3NC(CCCc3ccc4nc(NC(Cc(cc5)ccc5NC(C)=O)=O)[s]c4c3)=O)=O)[s]c2c1)=O ZWLSFGVKQKSTIV-UHFFFAOYSA-N 0.000 description 1
- DMMWYVSKCUJKCJ-UHFFFAOYSA-N Cc1ccc2nc(NC(Cc(cc3)ccc3Br)=O)[s]c2c1 Chemical compound Cc1ccc2nc(NC(Cc(cc3)ccc3Br)=O)[s]c2c1 DMMWYVSKCUJKCJ-UHFFFAOYSA-N 0.000 description 1
- COWQSUOQAGWHAL-UHFFFAOYSA-N Cc1ccc2nc(NC(Cc(cc3)ccc3N(C)C)=O)[s]c2c1 Chemical compound Cc1ccc2nc(NC(Cc(cc3)ccc3N(C)C)=O)[s]c2c1 COWQSUOQAGWHAL-UHFFFAOYSA-N 0.000 description 1
- BKBSVEHXUFRMOK-UHFFFAOYSA-N Cc1ccc2nc(NC(Cc(cc3)ccc3O)=O)[s]c2c1 Chemical compound Cc1ccc2nc(NC(Cc(cc3)ccc3O)=O)[s]c2c1 BKBSVEHXUFRMOK-UHFFFAOYSA-N 0.000 description 1
- AOCXQRAZWZBOCN-UHFFFAOYSA-N Cc1ccc2nc(NC(Cc3ccccc3)=O)[s]c2c1 Chemical compound Cc1ccc2nc(NC(Cc3ccccc3)=O)[s]c2c1 AOCXQRAZWZBOCN-UHFFFAOYSA-N 0.000 description 1
- LEFVZPTXIUOCFC-UHFFFAOYSA-N N/C(/Nc1nc(cccc2)c2[nH]1)=N\C(CCc1cccnc1)=O Chemical compound N/C(/Nc1nc(cccc2)c2[nH]1)=N\C(CCc1cccnc1)=O LEFVZPTXIUOCFC-UHFFFAOYSA-N 0.000 description 1
- VNFGFTRQFPELFE-UHFFFAOYSA-N N/C(/Nc1nc2ccccc2[nH]1)=N\C(Cc1ccncc1)=O Chemical compound N/C(/Nc1nc2ccccc2[nH]1)=N\C(Cc1ccncc1)=O VNFGFTRQFPELFE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925608P | 2014-01-09 | 2014-01-09 | |
| US61/925,608 | 2014-01-09 | ||
| PCT/US2015/010901 WO2015106158A1 (en) | 2014-01-09 | 2015-01-09 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502069A JP2017502069A (ja) | 2017-01-19 |
| JP2017502069A5 true JP2017502069A5 (enExample) | 2018-02-15 |
| JP6542236B2 JP6542236B2 (ja) | 2019-07-10 |
Family
ID=53524387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545898A Active JP6542236B2 (ja) | 2014-01-09 | 2015-01-09 | 有機化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9944648B2 (enExample) |
| EP (1) | EP3091982B1 (enExample) |
| JP (1) | JP6542236B2 (enExample) |
| KR (1) | KR20160101197A (enExample) |
| CN (1) | CN106029075A (enExample) |
| AU (1) | AU2015204566A1 (enExample) |
| BR (1) | BR112016016098A2 (enExample) |
| CA (1) | CA2935985A1 (enExample) |
| ES (1) | ES2728932T3 (enExample) |
| MX (1) | MX2016008968A (enExample) |
| RU (1) | RU2016132574A (enExample) |
| WO (1) | WO2015106158A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2728932T3 (es) | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| WO2016176473A1 (en) * | 2015-04-28 | 2016-11-03 | Sanford-Burnham Medical Researc Institute | Apelin receptor agonists and methods of use thereof |
| WO2021190615A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
| WO2021190616A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Methods for inhibiting casein kinases |
| EP4146654A1 (en) * | 2020-05-07 | 2023-03-15 | Adorx therapeutics Limited | Antagonists of the adenosine a2a receptor |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH04503205A (ja) * | 1988-05-02 | 1992-06-11 | ナフッチィ，エヌ，エリック | 神経学的活性化合物 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6060296A (en) | 1991-07-03 | 2000-05-09 | The Salk Institute For Biological Studies | Protein kinases |
| US5157378A (en) | 1991-08-06 | 1992-10-20 | North-South Corporation | Integrated firefighter safety monitoring and alarm system |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5545580A (en) | 1995-09-19 | 1996-08-13 | United Microelectronics Corporation | Multi-state read-only memory using multiple polysilicon selective depositions |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6288089B1 (en) | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| DE60001229T2 (de) | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp., Philadelphia | Triarylimidazole |
| ATE322016T1 (de) | 1999-06-08 | 2006-04-15 | Aventis Pharma Inc | Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse |
| ES2213996T3 (es) | 1999-12-08 | 2004-09-01 | Centre National De La Recherche Scientifique (Cnrs) | Uso de himenialdisina o sus derivados en la fabricacion de medicamentos. |
| US6448057B1 (en) | 2001-03-22 | 2002-09-10 | Applera Corporation | Isolated human casein kinase proteins, nucleic acid molecules encoding human casein kinase proteins, and uses thereof |
| AU2002316279B2 (en) | 2001-06-18 | 2007-08-23 | The Rockefeller University | Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| EP1423103A4 (en) | 2001-08-10 | 2008-03-19 | Univ Rockefeller | COMPOSITIONS AND METHOD FOR MODULATING DARPP-32 PHOSPHORYLATION |
| US7008666B2 (en) | 2001-11-26 | 2006-03-07 | Hormos Nutraceutical Oy Ltd. | Method of inhibiting overactivity of phagocytes or lymphocytes in an individual |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| GB0314943D0 (en) | 2003-06-25 | 2003-07-30 | Proteome Sciences Plc | Screening methods |
| WO2005105987A1 (en) | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with casein kinase 1, delta, isoform 2 (csnk1d iso 2) |
| ES2425179T3 (es) | 2006-10-25 | 2013-10-11 | The Rockefeller University | Métodos para el tratamiento de trastornos relacionados con beta-amiloide y composiciones para los mismos |
| FR2918061B1 (fr) * | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| FR2918986B1 (fr) * | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
| US8633200B2 (en) * | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| PL2710018T3 (pl) * | 2011-05-19 | 2022-04-04 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Związki makrocykliczne jako inhibitory kinaz białkowych |
| EP2802590B1 (en) * | 2012-01-10 | 2017-03-01 | F. Hoffmann-La Roche AG | Thienopyrimidine compounds |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| ES2728932T3 (es) | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
-
2015
- 2015-01-09 ES ES15735265T patent/ES2728932T3/es active Active
- 2015-01-09 RU RU2016132574A patent/RU2016132574A/ru unknown
- 2015-01-09 US US15/110,613 patent/US9944648B2/en active Active
- 2015-01-09 AU AU2015204566A patent/AU2015204566A1/en not_active Abandoned
- 2015-01-09 BR BR112016016098A patent/BR112016016098A2/pt not_active IP Right Cessation
- 2015-01-09 KR KR1020167021570A patent/KR20160101197A/ko not_active Withdrawn
- 2015-01-09 MX MX2016008968A patent/MX2016008968A/es unknown
- 2015-01-09 CA CA2935985A patent/CA2935985A1/en not_active Abandoned
- 2015-01-09 EP EP15735265.9A patent/EP3091982B1/en active Active
- 2015-01-09 WO PCT/US2015/010901 patent/WO2015106158A1/en not_active Ceased
- 2015-01-09 CN CN201580009759.9A patent/CN106029075A/zh active Pending
- 2015-01-09 JP JP2016545898A patent/JP6542236B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505898A5 (enExample) | ||
| JP2017502069A5 (enExample) | ||
| RU2009147708A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842 | |
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2019517487A5 (enExample) | ||
| JP2012526736A5 (enExample) | ||
| EA023824B1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| ME02390B (me) | Inhibitori beta sekretaze | |
| JP2015516429A5 (enExample) | ||
| JP2013544277A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2012526735A5 (enExample) | ||
| JP2013519684A (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法 | |
| JP2013519685A (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| JP2017538753A5 (enExample) | ||
| JP2022549335A5 (enExample) | ||
| RU2016132574A (ru) | Органические соединения | |
| JP2017523202A5 (enExample) | ||
| JP2013518914A5 (enExample) | ||
| JP2024160326A (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| JP2016537338A5 (enExample) | ||
| JP2019516756A5 (enExample) |